November 20, 2007 - Biogen Idec (NASDAQ: BIIB) and Neurimmune Therapeutics AG today announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the
treatment of Alzheimer's disease (AD)...Neurimmune will conduct research to identify potential therapeutic antibodies using the company's Reverse Translational Medicine (RTM) platform. Biogen Idec will be responsible for the development and commercialization of all products...
Biogen's Press Release -
Neurimmune's Press Release -
